PR-619 是一种 DUB 抑制剂，作用于 USP4，USP8，USP7，USP2 和 USP5，EC50 分别为 3.93，4.9，6.86，7.2 和 8.61 μM。PR-619 可诱导内质网应激和内质网应激相关的凋亡。

Pitstop 2 是一种网格蛋白抑制剂，可通过与网格蛋白的末端域相关联来抑制网格蛋白介导的内吞作用 (CME)。Pitstop 2 有潜力用于抗癌的研究。

DBCO-PEG4-VC-PAB-MMAE, an ADC linker comprising DBCO-PEG4-VC-PAB coupled with the tubulin polymerization inhibitor MMAE, serves as a key component in the formulation of antibody-drug conjugates (ADCs). MMAE, a synthetic derivative of dolastatin 10, inhibits tubulin polymerization, acting as a potent mitotic inhibitor.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a potent antitumor ADC drug-linker conjugate that utilizes Eribulin, an anti-microtubule agent, connected through the Mal-(CH2)5-Val-Cit-PAB linker.

Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

NAMPT inhibitor-linker 2, a drug-linker conjugate for antibody-drug conjugates (ADCs), comprises an NAMPT inhibitor payload and a linker. When combined with an anti-c-Kit monoclonal antibody to form ADC-4, it demonstrates potent efficacy against c-Kit expressing cell lines, including GIST-T1 and NCI-H526, with IC50 values of <7 pM and 40 pM, respectively.

Mal-PEG4-VA-PBD is a drug-linker conjugate for Antibody-Drug Conjugates (ADCs), comprising the antitumor antibiotic Pyrrolobenzodiazepine (PBD), connected through Mal-PEG4-VA.